Herald Investment Management Ltd grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 68.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,500 shares of the medical instruments supplier's stock after acquiring an additional 5,083 shares during the period. Herald Investment Management Ltd owned 0.23% of Mesa Laboratories worth $1,483,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in MLAB. Raymond James Financial Inc. bought a new stake in Mesa Laboratories during the 4th quarter valued at $32,677,000. Ameriprise Financial Inc. increased its position in shares of Mesa Laboratories by 191.8% during the fourth quarter. Ameriprise Financial Inc. now owns 151,862 shares of the medical instruments supplier's stock worth $20,026,000 after acquiring an additional 99,819 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Mesa Laboratories by 1,390.4% in the 4th quarter. Jane Street Group LLC now owns 34,399 shares of the medical instruments supplier's stock worth $4,536,000 after acquiring an additional 32,091 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Mesa Laboratories by 14,805.8% in the 1st quarter. GAMMA Investing LLC now owns 18,036 shares of the medical instruments supplier's stock worth $2,140,000 after acquiring an additional 17,915 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Mesa Laboratories by 27.7% in the 4th quarter. Bank of America Corp DE now owns 68,474 shares of the medical instruments supplier's stock valued at $9,030,000 after acquiring an additional 14,863 shares in the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.
Mesa Laboratories Stock Up 1.3%
NASDAQ:MLAB traded up $0.82 on Friday, hitting $64.29. The stock had a trading volume of 139,979 shares, compared to its average volume of 146,846. Mesa Laboratories, Inc. has a 1 year low of $55.45 and a 1 year high of $155.12. The firm's fifty day simple moving average is $87.56 and its two-hundred day simple moving average is $112.40. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.47 and a current ratio of 0.66. The stock has a market cap of $353.60 million, a P/E ratio of -459.21 and a beta of 0.83.
Mesa Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 29th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, August 29th. Mesa Laboratories's dividend payout ratio is -457.14%.
Insider Buying and Selling at Mesa Laboratories
In other news, CFO John Sakys sold 642 shares of Mesa Laboratories stock in a transaction on Monday, June 16th. The stock was sold at an average price of $97.12, for a total transaction of $62,351.04. Following the sale, the chief financial officer directly owned 12,865 shares in the company, valued at $1,249,448.80. The trade was a 4.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian David Archbold sold 472 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $97.12, for a total transaction of $45,840.64. Following the sale, the senior vice president owned 558 shares of the company's stock, valued at $54,192.96. This trade represents a 45.83% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,053 shares of company stock worth $296,507 in the last quarter. 4.90% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
A number of brokerages have commented on MLAB. Wells Fargo & Company raised Mesa Laboratories from an "underweight" rating to an "equal weight" rating and decreased their price objective for the stock from $100.00 to $67.00 in a report on Thursday. Wall Street Zen lowered Mesa Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday.
View Our Latest Report on Mesa Laboratories
Mesa Laboratories Profile
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Recommended Stories

Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.